Retrospective Analysis of Scintigraphic Examinations in Patients with Inflammatory Rheumatic Diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039638

Enrollment

200

Registered

2026-03-31

Start date

2026-03-16

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis: M06.00, M06.90 Psoriatic arthritis: L40.5 + M07.10 Axial spondyloarthritis: M45.00 M06 M06.90 L40.5 M07.10 M45

Interventions

Group 1: Patients with rheumatoid arthritis (RA) Analysis of medical records and imaging data from patients with rheumatoid arthritis (RA) who were treated at the Rheumazentrum Ruhrgebiet or the Depar

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Clinical diagnosis of a rheumatic disease (PsA, axSpA, or RA) - Undergoing a scintigraphy for clinical reasons - Treatment with a bDMARD

Exclusion criteria

Exclusion criteria: -Incomplete data set -Under 18 years of age

Design outcomes

Primary

Measure	Time frame
The primary endpoint being investigated is the relationship between the extent and distribution pattern of inflammation as shown by scintigraphy and subsequent treatment success with a bDMARD.	—

Secondary

Measure	Time frame
A secondary endpoint is the correlation between scintigraphic markers of inflammation, serological parameters, and other imaging parameters (MRI, X-ray, and ultrasound) from routine clinical practice.	—

Countries

Germany

Contacts

Public ContactPhilipp Hagemann

Rheumazentrum Ruhrgebiet am Marien-Hospital Herne, Universitätsklinik der Ruhr-Universität Bochum

philipp.hagemann@elisabethgruppe.de+492325 592 859

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026